Want to see ARVN full AI Analyst Report?
ARVN Stock Chart & Stats
$8.03
-$0.09(-1.11%)
At close: 4:00 PM EDT
$8.03
-$0.09(-1.11%)
Day’s Range― - ―
52-Week Range$6.96 - $14.51
Previous Close$8.04
Volume385.67K
Average Volume (3M)705.62K
Market Cap
$605.48M
Enterprise Value-$13.73
Total Cash (Recent Filing)$567.90M
Total Debt (Recent Filing)$8.00M
Price to Earnings (P/E)50.9
Beta1.38
Next Earnings
Nov 10, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.19
Shares Outstanding65,386,190
10 Day Avg. Volume585,545
30 Day Avg. Volume705,615
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.77
Price to Sales (P/S)2.93
P/FCF Ratio-2.79
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$14.96Price Target Upside86.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.39
Revenue Forecast (FY)$273.92M
Bulls Say, Bears Say
Bulls Say
PROTAC Validation And Partnered CommercializationVEPPANU’s approval validates Arvinas’s protein-degradation platform, while the Rigel partnership transfers commercialization responsibilities and creates potential milestone and royalty income beyond near-term collaboration payments.
Strong Liquidity And Low LeverageSubstantial liquidity, minimal debt and a multiyear runway give Arvinas flexibility to fund clinical development without immediate balance-sheet pressure, supporting continued investment through important regulatory and clinical milestones.
Broad Pipeline And Disciplined Capital AllocationMultiple programs across oncology and neurology diversify the development platform, while partnering ARV-806 and reducing R&D spending can concentrate capital on assets with nearer-term data and greater strategic relevance.
Bears Say
Persistent Operating Cash BurnDeeply negative operating and free cash flow show that reported profitability has not translated into self-funded operations. Continued clinical spending may require future partnering, financing or additional cost controls if cash generation does not improve.
Revenue Is Dependent On Nonrecurring CollaborationsRecent revenue strength was materially driven by one-time accounting recognition and milestone events rather than recurring product sales. This makes future revenue volatile and leaves durable earnings dependent on new partnerships or approvals.
Clinical Execution And Development Timing RiskSlow dose escalation and regulatory delays can defer clinical readouts, extend development timelines and increase costs. They also reduce near-term evidence for pipeline value, making successful execution across several programs more important.
Arvinas Holding Company News
ARVN FAQ
What was Arvinas Holding Company’s price range in the past 12 months?
Arvinas Holding Company lowest stock price was $6.96 and its highest was $14.51 in the past 12 months.
What is Arvinas Holding Company’s market cap?
Arvinas Holding Company’s market cap is $605.48M.
When is Arvinas Holding Company’s upcoming earnings report date?
Arvinas Holding Company’s upcoming earnings report date is Nov 10, 2026 which is in 82 days.
How were Arvinas Holding Company’s earnings last quarter?
Arvinas Holding Company released its earnings results on Aug 04, 2026. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of -$0.374 by $2.954.
Is Arvinas Holding Company overvalued?
According to Wall Street analysts Arvinas Holding Company’s price is currently Undervalued.
Does Arvinas Holding Company pay dividends?
Arvinas Holding Company does not currently pay dividends.
What is Arvinas Holding Company’s EPS estimate?
Arvinas Holding Company’s EPS estimate is -0.86.
How many shares outstanding does Arvinas Holding Company have?
Arvinas Holding Company has 65,386,190 shares outstanding.
What happened to Arvinas Holding Company’s price movement after its last earnings report?
Arvinas Holding Company reported an EPS of $2.58 in its last earnings report, beating expectations of -$0.374. Following the earnings report the stock price went up 11.663%.
Which hedge fund is a major shareholder of Arvinas Holding Company?
Currently, no hedge funds are holding shares in ARVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arvinas Holding Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.96 (86.36% Upside)
$14.96 (86.36% Upside)
Blogger Sentiment
Bullish
ARVN Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 174.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $517.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.7%
Last 30 Days >0.1%
Last 30 Days >0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.76%
Trailing 12-Months
Company Description
Arvinas Holding Company
Arvinas Holding Company (ARVN) is a clinical-stage biotechnology company focused on discovering and developing therapies that eliminate disease-causing proteins using its PROTAC (PROteolysis TArgeting Chimera) protein degrader technology. The company operates in the biopharmaceutical sector and advances a pipeline of targeted protein degradation candidates, primarily in oncology and other serious diseases, with programs spanning internal development and partnered development.
ARVN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized major strategic and scientific milestones — notably the first PROTAC approval (VEPPANU), substantial one-time revenue recognition and continued advancement of multiple clinical and preclinical programs with clear near-term data catalysts. Arvinas has strengthened focus on Phase I oncology and neurology assets, reported meaningful cost reductions and maintained a cash runway into H2 2028. Offsetting these positives are execution and timing challenges: ARV-393 enrollment was slowed by conservative starting doses (yielding mostly sub-efficacious cohort data in 2026), ARV-102 experienced regulatory delays pushing patient trials into 2027, cash declined ~17% YoY, and recent revenue was materially driven by one-time licensing and milestone events. Overall, the call leans positive because substantive strategic wins, upcoming clinical catalysts and a solid balance sheet (despite the cash decline) outweigh the program-specific delays and one-time accounting impacts.View all ARVN earnings summariesARVN Stock 12 Month Forecast
Average Price Target
$14.96
▲(86.36% Upside)
Technical Analysis
AnaptysBio
―
Meiragtx Holdings
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
3.62% Insiders
19.04% Mutual Funds
21.60% Other Institutional Investors
40.94% Public Companies and
Individual Investors